.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Accenture
AstraZeneca
McKesson
Citi
Covington
US Department of Justice
Fish and Richardson
Express Scripts

Generated: December 14, 2017

DrugPatentWatch Database Preview

VIDEX EC Drug Profile

« Back to Dashboard

When do Videx Ec patents expire, and when can generic versions of Videx Ec launch?

Videx Ec is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in VIDEX EC is didanosine. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the didanosine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-001Oct 31, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-004Oct 31, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-002Oct 31, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-003Oct 31, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIDEX EC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-004Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-001Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-004Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-003Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-002Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-003Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-002Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-001Oct 31, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VIDEX EC

Drugname Dosage Strength RLD Submissiondate
didanosineDelayed-release Capsules200 mg, 250 mg and 400 mgVidex EC6/1/2004

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Mallinckrodt
Express Scripts
McKesson
Chinese Patent Office
Daiichi Sankyo
McKinsey
Argus Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot